Drug Trial Radar · NCT04501120
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
682
Planned (sponsor's estimate)
Start
Sep 28, 2020
Primary completion
Sep 2028
Study completion Sep 2029
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Suzhou Yasheng Pharmaceutical Co., Ltd.
- First posted
- Aug 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, pharmacokinetic profile of Lisaftoclax (APG-2575) single agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related myeloid malignancies.
Conditions
- Relapsed/Refractory Acute Myeloid Leukaemia
- Myeloid Malignancy
Interventions
Lisaftoclax (APG-2575)Drug
Lisaftoclax (APG-2575) orally once daily, every 28 days as a cycle.
Reduced-dose HHTDrug
1mg IV QD on Days 1-14 (28-day cycle).
standard-dose HHTDrug
2mg/m\^2 IV QD on Days 1-7 (28-day cycle).
AzacitidineDrug
75 mg/m\^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
Lisaftoclax (APG-2575)Drug
Lisaftoclax (APG-2575) orally once daily for 14 days, every 28 days as a cycle.
olverembatinibDrug
orally, with meals, QOD, every 28 days as a cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Limiting Toxicities (DLT)Time frame: 28 days
- Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)Time frame: 28 days
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guandong, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Henan Tumor Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital medical college Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Zhongnan Hospital of Hunan university
Wuhan, Hubei, China · Recruiting
Xiangya Hospital Central South University
Changsha, Hunan, China · Recruiting
The First affiliated hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
Shanghai The Sixth People' s Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
the First Affiliated Hospital, College of Medicine, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.